QSAM Biosciences opens enrollment of second cohort in Phase 1 study of CycloSam

QSAM Biosciences announces the opening of enrollment into the 2nd grouping of participants after completing Cohort 1 in February in its Phase 1 study evaluating CycloSam in the treatment of bone cancer. "We have met all criteria to continue patient enrollment at a higher dose level in the next group of patients," stated Douglas Baum, CEO. "We are pleased with the safety data and early signs of efficacy, and we are now moving forward with three active clinical trial sites to continue to recruit, screen and enroll participants in this important study evaluating the safety and early efficacy of CycloSam(R) in patients with metastatic bone cancer." Baum continued: "With almost $3 million in funding received in our recently completed private placement, and conversion of all of our outstanding convertible notes into common stock, QSAM is in a much stronger position to advance our clinical trials, achieve several important milestones this year, and create a solid foundation for growth and value creation."